Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Withdrawn 1Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 37Neoplasms, Plasma Cell 11Recurrence 6Lymphoma, Mantle-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Peripheral Nervous System Diseases 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Glioblastoma 2Waldenstrom Macroglobulinemia 1Renal Insufficiency 1Rectal Neoplasms 1Pathologic Complete Response 1Paraproteinemias 1Pancreatic Neoplasms 1Ovarian Neoplasm Epithelial 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm, Residual 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Liver Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Plasma Cell 1Leukemia 1Hypoxia 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Cyclophosphamide 9Prednisone 8Etoposide 6Vincristine 5Gemcitabine 5Lenalidomide 4Doxorubicin 4Dexamethasone 3Azacitidine 3liposomal doxorubicin 2endostar protein 2apatinib 2VAP-cyclo protocol 2Ifosfamide 2Cisplatin 2sintilimab 1romidepsin 1ivarmacitinib 1fludarabine phosphate 1fludarabine 1camrelizumab 1Vinorelbine 1Valproic Acid 1Transplantation, Autologous 1TQ-B3525 1Rituximab 1Prednisolone 1Polymerase Chain Reaction 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, T-Cell, Peripheral × Bortezomib × Clear all
NCT04061772 2019-08-20

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Zhejiang Cancer Hospital

Phase 2 Unknown
54 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡